Active Not Recruiting NA INTERVENTIONAL 1-arm NCT05529862

Trans-RosaLEE Study: a Biomarker-directed, Translational Study (TransRosaLEE)

Trans-RosaLEE Study: a Biomarker-directed, Translational Study of High-throughput Molecular Profiling of HR+/HER2- Metastatic Breast Cancer Treated With Endocrine Therapy and Ribociclib.

Sponsor: Institut Paoli-Calmettes

Conditions Advanced or Metastatic Breast Cancer (BC)

Interventions Post treatment biopsy Post treatment blood sampling Pre treatment blood sampling Pre-treatment biopsy

Updated 6 times since 2022 Last updated: Jan 20, 2026 Started: Jun 20, 2023 Primary completion: Nov 1, 2028 Completion: Nov 1, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Advanced or Metastatic Breast Cancer (BC), this trial is ongoing. The trial is conducted by Institut Paoli-Calmettes and has accumulated 6 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting NA

Status: Recruiting → Active Not Recruiting
Sep 2024 — Feb 2026 [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
Jul 2023 — Jul 2024 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Dec 2022 — Jul 2023 [monthly]

Not Yet Recruiting NA

▶ Show 1 earlier version

Sep 2022 — Dec 2022 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut Paoli-Calmettes
Novartis Pharmaceuticals

Data source: Institut Paoli-Calmettes

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Marseille, France